DAY101
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Low-grade Glioma
Conditions
Low-grade Glioma
Trial Timeline
Feb 27, 2018 → Dec 31, 2025
NCT ID
NCT03429803About DAY101
DAY101 is a phase 1 stage product being developed by Day One Biopharmaceuticals for Low-grade Glioma. The current trial status is completed. This product is registered under clinical trial identifier NCT03429803. Target conditions include Low-grade Glioma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03429803 | Phase 1 | Completed |
Competing Products
13 competing products in Low-grade Glioma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Rabeprazole Sodium | Eisai | Pre-clinical | 23 |
| Binimetinib 15 MG | Ono Pharmaceutical | Phase 2 | 52 |
| Everolimus | Novartis | Phase 2 | 52 |
| MEK162, MEK inhibitor; oral + Physician's choice chemotherapy | Pfizer | Phase 3 | 76 |
| Fludarabine Phosphate (Fludara) + Rituximab | Sanofi | Phase 2 | 51 |
| rituximab | Biogen | Phase 3 | 74 |
| Tovorafenib | Ipsen | Phase 1 | 30 |
| Tovorafenib | Day One Biopharmaceuticals | Phase 2 | 47 |
| Tovorafenib + Chemotherapeutic Agent | Day One Biopharmaceuticals | Phase 3 | 72 |
| Tovorafenib | Day One Biopharmaceuticals | Pre-clinical | 18 |
| TYRA-300 60mg + TYRA-300 50mg + TYRA-300 Dose TBD | Tyra Biosciences | Phase 2 | 47 |
| rhuFlt3L/CDX-301 + Poly-ICLC | Celldex Therapeutics | Phase 1/2 | 36 |
| combined therapy with rh-ES and CV | Brain Biotech | Phase 2 | 44 |